Endoscopic bariatric therapies.

Gastrointest Endosc

Published: May 2015

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gie.2015.02.023DOI Listing

Publication Analysis

Top Keywords

endoscopic bariatric
4
bariatric therapies
4
endoscopic
1
therapies
1

Similar Publications

Background: Transoral outlet reduction endoscopy (TORe) and glucagon-like peptide-1 agonist, liraglutide, have individually shown promise in managing weight regain after Roux-en-Y gastric bypass. However, combined effects of adjunctive liraglutide to TORe remain unexplored. A cross-over design was utilized to evaluate the efficacy of liraglutide treatment when initiated immediately post-TORe or 1 year post-TORe.

View Article and Find Full Text PDF

For patients considering bariatric surgery, it is essential to have clear answers to common questions to ensure the success of the procedure. Patients should understand that surgery is not a quick fix but a tool that must be complemented by lifestyle changes, including dietary adjustments and regular physical activity. The procedure carries potential risks that should be weighed against the potential benefits.

View Article and Find Full Text PDF

Obesity is a major global health problem and at the same time a financial burden for social security systems. For a long time, conventional lifestyle interventions have tried unsuccessfully to find a solution. It has been proven that only interventions that ultimately address the central control centers of hunger, appetite and satiety will lead to sustained weight loss.

View Article and Find Full Text PDF

While the prevalence of overweight and obesity is rising in Africa, the practice of bariatric surgery remains limited in our country, Cameroon. Weight loss outcomes following sleeve gastrectomy (SG), the most widely used bariatric surgery technique worldwide, have not yet been studied in our context. The medical records of all patients who underwent SG in our surgery department between January 1, 2016, and September 30, 2020, were reviewed retrospectively.

View Article and Find Full Text PDF

Background: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supraphysiological doses in youth to manage androgen excess and growth acceleration. These patients experience higher obesity rates, hypertension, and glucose metabolism issues, complicating long-term health management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!